RIGL — Rigel Pharmaceuticals, Inc.

Summary of Rigel Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $69.5 million for Q3 2025, a 65% increase year-over-year.
• Net Product Sales: $64.1 million, with significant contributions from:
  • TAVALISSE: $44.7 million (70% growth YoY)
  • GAVRETO: $11.1 million (56% growth YoY)
  • REZLIDHIA: $8.3 million (50% growth YoY)
• Net Income: $27.9 million, up from $12.4 million in Q3 2024.
• Cash Position: Increased to $137.1 million from $77.3 million at the end of 2024.
• Year-to-Date Revenue: $166.6 million, surpassing total revenue for all of 2024.

2. Strategic Updates and Business Highlights:

• Rigel's strategy focuses on expanding its hematology and oncology business through strong commercial performance and pipeline development.
• Progress in clinical trials, including:
  • R289 (dual IRAK1 and IRAK4 inhibitor) in Phase Ib for lower-risk MDS, with data to be presented at the ASH Annual Meeting.
  • Olutasidenib is being evaluated in multiple studies, including collaborations with MD Anderson and the CONNECT consortium for high-grade glioma.
• Rigel is exploring additional in-licensing opportunities to enhance its product portfolio.

3. Forward Guidance and Outlook:

• Revenue Guidance Raised: Total revenue expected to be $285 million to $290 million for 2025, up from $270 million to $280 million.
• Net Product Sales Guidance: Updated to $225 million to $230 million, reflecting anticipated growth of 55% to 59% compared to 2024.
• Rigel aims to maintain positive net income while funding clinical development opportunities.

4. Bad News, Challenges, or Points of Concern:

• The termination of the CNS penetrant program for ocadusertib by Eli Lilly, although the collaboration remains strong for other indications.
• Competitive pressures from existing therapies like RYTELO in the MDS space, with ongoing discussions about the positioning of R289 against such competitors.
• The need to demonstrate significant clinical efficacy in upcoming studies to secure a favorable regulatory pathway and market acceptance.

5. Notable Q&A Insights:

• Questions regarding the competitive positioning of R289 highlighted the differences in patient populations compared to RYTELO, with Rigel focusing on heavily pretreated patients.
• Discussions on the potential for priority review for R289, contingent on the evolving data from ongoing studies.
• Clarifications on gross-to-net dynamics indicated improvements in patient affordability and access, contributing to strong sales growth.
• Expectations for the upcoming ASH meeting were discussed, with anticipation for updated data on R289 and its implications for future clinical trials.

Overall, Rigel Pharmaceuticals reported a strong quarter with significant revenue growth and strategic advancements in its product pipeline, while also addressing competitive challenges and the need for continued clinical success.